{{Drugbox
| IUPAC_name = quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate
| image = FUB-PB-22_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_DE = Anlage II
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1800098-36-5
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 91936864
| ChemSpiderID      = 29763736
| smiles            = Fc1ccc(cc1)Cn1cc(c2c1cccc2)C(=O)Oc1cccc2c1nccc2
| StdInChI          = 1S/C25H17FN2O2/c26-19-12-10-17(11-13-19)15-28-16-21(20-7-1-2-8-22(20)28)25(29)30-23-9-3-5-18-6-4-14-27-24(18)23/h1-14,16H,15H2
| StdInChIKey       = ROHVURVXAOMRJY-UHFFFAOYSA-N
| UNII = DS46154N3F

<!--Chemical data-->
| C=25 | H=17 | F=1 | N=2 | O=2
| molecular_weight = 396.41 g/mol
}}

'''FUB-PB-22''' is an [[indole]]-based [[synthetic cannabinoid]] that is a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1275 | title=FUB-PB-22 | publisher=Southern Association of Forensic Scientists | accessdate=23 July 2015}}</ref><ref name="Uchiyama_2015">{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-015-0268-7 | title=A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products |author1=Nahoko Uchiyama |author2=Yoshihiko Shimokawa |author3=Ruri Kikura-Hanajiri |author4=Yosuke Demizu |author5=Yukihiro Goda |author6=Takashi Hakamatsuka | journal=Forensic Toxicology |date=February 2015  | doi=10.1007/s11419-015-0268-7 | pmid=26257833 | pmc=4525202 | volume=33 | pages=244–259}}</ref>

==Pharmacology==
FUB-PB-22 acts as a [[full agonist]] with a [[Affinity (pharmacology)#Protein-ligand binding|binding affinity]] of 0.386nM at [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and 0.478nM at [[Cannabinoid receptor type 2|CB<sub>2</sub>]] [[cannabinoid]] receptors.<ref>{{cite journal|first1=Cornelius|last1=Hess|first2=ClaraT.|last2=Schoeder|first3=Thanigaimalai|last3=Pillaiyar|first4=Burkhard|last4=Madea|title=Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice|journal=Forensic Toxicology|date=1 July 2016|issn=1860-8965|pages=329–343|volume=34|issue=2|doi=10.1007/s11419-016-0320-2|first5=ChristaE.|last5=Müller|pmid=27429655|pmc=4929166}}</ref>

== Legal status ==

FUB-PB-22 is a [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled substance in Germany. It was scheduled in Japan in July 2014.

As of October 2015 FUB-PB-22 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

It is also banned in Sweden.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/maj/cannabinoider-foreslas-bli-klassificerade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassificerade som hälsofarlig vara | publisher=Folkhälsomyndigheten | date=28 May 2014 | accessdate=23 July 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-PB-22]]
* [[AM-2201]]
* [[QUCHIC|BB-22]]
* [[FUB-JWH-018]]
* [[AB-FUBINACA]]
* [[ADB-FUBINACA]]
* [[AMB-FUBINACA]]
* [[FDU-PB-22]]
* [[FUB-144]]
* [[FUB-APINACA]]
* [[FUB-NNE1]]
* [[MDMB-FUBICA]]
* [[MDMB-FUBINACA]]
* [[PB-22]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:Indolecarboxylates]]


{{cannabinoid-stub}}